Process of reporting serious adverse events (SAE) during a regulatory Download Scientific Diagram Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database Scientific Reports Sermorelin: Benefits, FDA Status & Safety in 2025 Healthon From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Under reporting of harm in clinical trials The Lancet Oncology Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab